Brief: Diamyd Reports Follow-Up In Phase IIb Diamyd Trial

Diamyd Medical AB

16/06/2021 10:41

June 16 (Reuters) - Diamyd Medical AB  DMYDb.ST :
    * 24-MONTH FOLLOW-UP OF PHASE IIB DIAMYD® CLINICAL TRIAL
INDICATES
CONTINUED SIMILAR PROGRESSION AFTER 15 MONTHS
    * ACTIVELY TREATED INDIVIDUALS CARRYING HLA DR3-DQ2, IN
TOTAL 15
INDIVIDUALS, FOLLOWED THEIR EXPECTED TRAJECTORY FROM 15 TO 24
MONTH, SHOWING NO INDICATION OF DIMINISHING TREATMENT EFFECT
COMPARED TO THEIR PROGRESSION UP TO TO 15 MONTHS.
    * AS ALSO EXPECTED, SAFETY AT 24 MONTHS LOOKS GOOD WITH NO
DIFFERENCE IN ADVERSE EVENTS BETWEEN ACTIVELY TREATED AND
PLACEBO TREATED INDIVIDUALS

Source text for Eikon:  ID:nWkrbHcVTd 
Further company coverage:  DMYDb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))